Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF) . Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities
In Vitro
Oglufanide (IM862) (1-1000 μg/mL) exhibits dose dependent inhibition of angiogenesis in the chorioallantoic membrane assay with complete inhibition of β-FGF and VEGF-induced angiogenesis. ?\nOglufanide (L-glu-L-trp) (0-1000 μg/mL; 5 days) has no effect on the viability of either the tumor cell lines or HUVECs . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Oglufanide (L-glu-L-trp) (1-100 mg/kg/day; s.c.; 10 days) has antitumor activity in immunocompetent and immunodeficient mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 immune competent mice, Lewis lung carcinoma (LLC) xenograft; Balb/C athymic mice, M21 human melanoma xenograftDosage: 1, 10, 50 and 100 mg/kg/day Administration: Subcutaneous injection, 10 days Result: Resulted in a dose-dependent inhibition of LLC tumor growth in syngeneic immune competent mice and showed a dose-dependent decrease in tumor volumes of xenografts in Balb/C athymic mice implanted with M21 human melanoma cells.
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF) . Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infecti
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.